Hoppe C, Vichinsky E, Quirolo K, van Warmerdam J, Allen K, Styles L
Department of Hematology/Oncology, Children's Hospital Oakland, California 94609, USA.
J Pediatr Hematol Oncol. 2000 Jul-Aug;22(4):330-4. doi: 10.1097/00043426-200007000-00009.
The efficacy and side effects of hydroxyurea in young children with sickle cell disease are unknown. The authors followed-up eight young children (mean age 3.7 years) during therapy with hydroxyurea for an average of 137 weeks. Total and fetal hemoglobin levels rose with hydroxyurea therapy. Hospital admission rates and total hospital days decreased during hydroxyurea therapy. No unexpected toxicity occurred, and growth and development were unaffected. This pilot study suggests that hydroxyurea is safe and effective in young children with sickle cell disease.
羟基脲对镰状细胞病幼儿的疗效和副作用尚不清楚。作者对8名幼儿（平均年龄3.7岁）进行了羟基脲治疗随访，平均随访137周。羟基脲治疗期间，总血红蛋白和胎儿血红蛋白水平升高。羟基脲治疗期间，住院率和总住院天数下降。未出现意外毒性反应，生长发育未受影响。这项初步研究表明，羟基脲对镰状细胞病幼儿安全有效。
